Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants.
The unidimensional self-efficacy scale for MS (USE-MS): developing a patient based and patient reported outcome.
Safety Study of GNbAC1 in Multiple Sclerosis Patients
Confounding in association studies: month of birth and multiple sclerosis.
CLARITY – Safety and Efficacy of Oral Cladribine in Subjects with Relapsing-remitting Multiple Sclerosis (MS)
Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis.
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
Extracranial Venous abnormalities: A true pathological finding in patients with multiple sclerosis or an anatomical variant?
Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta.
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis
Multiple Sclerosis: Vitamin D and calcium as environmental determinants of prevalence (A Viewpoint)
Phenytoin (Dilantin) and acupuncture therapy in the treatment of intractable oral and facial pain.
Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis.
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.
The extent of ultrastructural spinal cord pathology reflects disease severity in experimental autoimmune encephalomyelitis.
Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: a Phase 1 study.
Neuroenhancement through cognitive training and anodal tDCS in multiple sclerosis.
[Multiple sclerosis : actuality and therapeutic prospects].
Amiloride Clinical Trial In Optic Neuritis (ACTION)
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Multiple sclerosis and progressive resistance training: a systematic review.
Santhera enters agreement with Columbia University to investigate additional potential of Catena® in MELAS
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

Pages